首页> 外文期刊>Molecular pharmacology. >Mutational Analysis and Modeling of Negative Allosteric Modulator Binding Sites in AMPA Receptors
【24h】

Mutational Analysis and Modeling of Negative Allosteric Modulator Binding Sites in AMPA Receptors

机译:AMPA受体中负变性调节剂结合位点的突变分析和建模

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) constitute a subclass of the ionotropic glutamate receptor superfamily, which functions as glutamate-gated cation channels to mediate the majority of excitatory neurotransmission in the central nervous system. AMPARs are therapeutic targets in a range of brain disorders associated with abnormal glutamate hyperactivity. Multiple classes of AMPAR inhibitors have been developed during the past decades, including competitive antagonists, ion channel blockers, and negative allosteric modulators (NAMs). At present, the NAM is the only class of AMPAR ligands that have been developed into safe and useful drugs in humans in the form of perampanel (Fycompa), which was recently approved for treatment of epilepsy. Compared with the detailed understanding of other AMPAR ligand classes, surprisingly little information has been available regarding the molecular mechanism of perampanel and other classes of NAMs at AMPARs; including the location and structure of NAM binding pockets in the receptor complex. However, structures of the AMPAR GluA2 in complex with NAMs were recently reported that unambiguously identified the NAM binding sites. In parallel with this work, our aim with the present study was to identify specific residues involved in the formation of the NAM binding site for three prototypical AMPAR NAMs. Hence, we have performed a mutational analysis of the AMPAR region that links the four extracellular ligand-binding domains to the central ion channel in the transmembrane domain region. Furthermore, we perform computational ligand docking of the NAMs into structural models of the homomeric GluA2 receptor and optimize side chain conformations around the NAMs to model how NAMs bind in this specific site. The new insights provide potentially valuable input for structure-based drug design of new NAMs.
机译:α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(AMPAR)构成离子型谷氨酸受体超家族的亚类,其用作谷氨酸门控阳离子通道,以介导中枢神经中的大多数兴奋性神经递血系统。 Ampars是一种与异常谷氨酸异常相关的脑疾病的治疗靶标。在过去的几十年中,已经开发了多种类别的AMPAR抑制剂,包括竞争性拮抗剂,离子通道阻滞剂和负变性调节剂(NAM)。目前,NAM是唯一一类已被制定为Perampanel(FYCompa)形式的人类安全和有用的药物,最近批准用于治疗癫痫症。与其他AMPAR配体课程的详细了解相比,有关Perampanel和其他Nams的分子机制,可令人惊讶的是在AMPars上的其他课堂;包括受体复合物中NAM结合口袋的位置和结构。然而,最近据报道,随着NAM的复合物中的AMPAR glua2的结构,明确识别NAM结合位点。与这项工作并行,我们的目前研究的宗旨是识别三个原型AMPAR NAM的NAM结合位点所涉及的特定残留物。因此,我们已经对跨膜结构域区域中的中央离子通道连接到与中央离子通道的突变分析进行了突变分析。此外,我们将NAM的计算配体对接成为均匀GLUA2受体的结构模型,并优化NAM周围的侧链构象以模拟NAMS如何在该特定部位中粘合。新的见解为新NAMS的结构为基础的药物设计提供了潜在的有价值的投入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号